These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 33199641)
21. Tissue-Specific Oncogenic Activity of KRAS Poulin EJ; Bera AK; Lu J; Lin YJ; Strasser SD; Paulo JA; Huang TQ; Morales C; Yan W; Cook J; Nowak JA; Brubaker DK; Joughin BA; Johnson CW; DeStefanis RA; Ghazi PC; Gondi S; Wales TE; Iacob RE; Bogdanova L; Gierut JJ; Li Y; Engen JR; Perez-Mancera PA; Braun BS; Gygi SP; Lauffenburger DA; Westover KD; Haigis KM Cancer Discov; 2019 Jun; 9(6):738-755. PubMed ID: 30952657 [No Abstract] [Full Text] [Related]
22. Ras GTPases: codon bias holds KRas down but not out. Bodemann BO; White MA Curr Biol; 2013 Jan; 23(1):R17-20. PubMed ID: 23305663 [TBL] [Abstract][Full Text] [Related]
23. Activating missense mutations in Ha-ras-1 genes in a malignant subset of bladder lesions induced by N-butyl-N-(4-hydroxybutyl)nitrosamine or N-[4-(5-nitro-2-furanyl)-2-thiazolyl]formamide. Jones RF; Debiec-Rychter M; Zukowski K; Wang CY Mol Carcinog; 1990; 3(6):393-402. PubMed ID: 2278634 [TBL] [Abstract][Full Text] [Related]
24. KRAS Alleles: The Devil Is in the Detail. Haigis KM Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387 [TBL] [Abstract][Full Text] [Related]
25. The role of p19 and p21 H-Ras proteins and mutants in miRNA expression in cancer and a Costello syndrome cell model. García-Cruz R; Camats M; Calin GA; Liu CG; Volinia S; Taccioli C; Croce CM; Bach-Elias M BMC Med Genet; 2015 Jul; 16():46. PubMed ID: 26138095 [TBL] [Abstract][Full Text] [Related]
26. p53 and p21/Waf1 protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater. Zhao B; Kimura W; Futakawa N; Muto T; Kubota K; Harihara Y; Takayama T; Makuuchi M Am J Gastroenterol; 1999 Aug; 94(8):2128-34. PubMed ID: 10445539 [TBL] [Abstract][Full Text] [Related]
27. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Hirai H; Kobayashi Y; Mano H; Hagiwara K; Maru Y; Omine M; Mizoguchi H; Nishida J; Takaku F Nature; 1987 Jun 4-10; 327(6121):430-2. PubMed ID: 3295562 [TBL] [Abstract][Full Text] [Related]
28. Transformation of NIH3T3 cells with synthetic c-Ha-ras genes. Kamiya H; Miura K; Ohtomo N; Koda T; Kakinuma M; Nishimura S; Ohtsuka E Jpn J Cancer Res; 1989 Mar; 80(3):200-3. PubMed ID: 2542206 [TBL] [Abstract][Full Text] [Related]
29. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF. Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035 [TBL] [Abstract][Full Text] [Related]
30. [Significance of oncogenes and growth factors in hypernephroma]. Peter S Urologe A; 1992 Jan; 31(1):24-7. PubMed ID: 1553800 [TBL] [Abstract][Full Text] [Related]
31. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma. Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673 [TBL] [Abstract][Full Text] [Related]
32. Activated Ki-ras proto-oncogene in spontaneously transformed and chemical tumor-derived cell lines related to the mouse lung alveologenic carcinoma. Leigh DA; Ferguson V; Bentel JM; Miller JO; Smith GJ Mol Carcinog; 1990; 3(6):387-92. PubMed ID: 2177605 [TBL] [Abstract][Full Text] [Related]
33. Targeting the RAS-dependent chemoresistance: The Warburg connection. Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815 [TBL] [Abstract][Full Text] [Related]
34. Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer. Zhong X; Zheng L; Shen J; Zhang D; Xiong M; Zhang Y; He X; Tanyi JL; Yang F; Montone KT; Chen X; Xu C; Xiang AP; Huang Q; Xu X; Zhang L Mol Cell Biol; 2016 Nov; 36(21):2742-2754. PubMed ID: 27550813 [TBL] [Abstract][Full Text] [Related]
35. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992 [TBL] [Abstract][Full Text] [Related]
36. MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. Choi YW; Song YS; Lee H; Yi K; Kim YB; Suh KW; Lee D Medicine (Baltimore); 2016 Apr; 95(15):e3321. PubMed ID: 27082577 [TBL] [Abstract][Full Text] [Related]
38. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Chi S; Kitanaka C; Noguchi K; Mochizuki T; Nagashima Y; Shirouzu M; Fujita H; Yoshida M; Chen W; Asai A; Himeno M; Yokoyama S; Kuchino Y Oncogene; 1999 Apr; 18(13):2281-90. PubMed ID: 10327074 [TBL] [Abstract][Full Text] [Related]
39. Pancreatic ductal adenocarcinomas induced in Syrian hamsters by N-nitrosobis(2-oxopropyl)amine contain a c-Ki-ras oncogene with a point-mutated codon 12. Fujii H; Egami H; Chaney W; Pour P; Pelling J Mol Carcinog; 1990; 3(5):296-301. PubMed ID: 2173932 [TBL] [Abstract][Full Text] [Related]
40. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]